Intercept Pharma (ICPT) Tops Q2 EPS by 88c

Intercept Pharma (NASDAQ: ICPT) reported Q2 EPS of ($0.33), $0.88 better than the analyst estimate of ($1.21). Revenue for the quarter came in at $96.6 million versus the consensus estimate of $82.95 million.

2021 Financial Guidance:

We are reiterating our full year 2021 worldwide Ocaliva net sales guidance of $325 million to $340 million as we monitor post-label update market dynamics.

We are reiterating our full year 2021 non-GAAP adjusted operating expense guidance of between $380 million to $410 million.

See “Non-GAAP Financial Measures” below. A quantitative reconciliation of projected non-GAAP adjusted operating expenses to total operating expenses is not available without unreasonable effort primarily due to our inability to predict with reasonable certainty the amount of future stock-based compensation expense.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Light & Wonder to report Q2 results Aug. 4, reaffirms FY26 outlook
• Trex raises 2026 guidance, names SBP as sole national distributor